Mankind Pharma (BOM:543904) EBIT: ₹29,720 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543904 Mankind Pharma Ltd BOM:543904
90 GF Score
Price ₹2,491.45
GF Value ₹2,934.91
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Mankind Pharma EBIT?

Mankind Pharma BOM:543904 -2.10% 90 EBIT is ₹29,720 Mil as of Mar. 2026. GuruFocus rates BOM:543904 with a GF Score™ of 90/100 and a GF Value™ of ₹2,934.91 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Mankind Pharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹8,009 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹29,720 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Mankind Pharma's annualized ROC % for the quarter that ended in Mar. 2026 was 9.34%. Mankind Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 59.80%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Mankind Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.77%.

Mankind Pharma  (BOM:543904) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Mankind Pharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=28272 * ( 1 - 15.13% )/( (0 + 256923)/ 1 )
=23994.4464/256923
=9.34 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=280795.3 - 19402.8 - ( 21958.5 - max(0, 65072.5 - 69542+21958.5))
=256923

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Mankind Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=32036.8/( ( (0 + max(0, 0)) + (37139.4 + max(16434.3, 0)) )/ 1 )
=32036.8/( ( 0 + 53573.7 )/ 1 )
=32036.8/53573.7
=59.80 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(17295.1 + 21444.8 + 8578.1) - (19402.8 + 0 + 11480.9)
=16434.3

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Mankind Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=29719.6/1072722.829
=2.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mankind Pharma EBIT Related Terms

Mankind Pharma EBIT Historical Data

* Premium members only.

The historical data trend for Mankind Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mankind Pharma EBIT Chart

Mankind Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial 20,303.79 17,115.13 24,257.60 29,372.20 29,660.80

Mankind Pharma Quarterly Data
Mar20 Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,059.70 7,111.40 7,937.00 6,662.00 8,009.20

BOM:543904 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mankind Pharma EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mankind Pharma's EV-to-EBIT falls into.


BOM:543904
90GF Score
Mankind Pharma Ltd BOM:543904
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mankind Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹29,720 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹29,720 Mil mean?
Mankind Pharma (BOM:543904) has a EBIT of ₹29,720 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Mankind Pharma.
Is Mankind Pharma's EBIT too high?
Mankind Pharma's current EBIT is ₹29,720 Mil. Overall, Mankind Pharma has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's EBIT compare to ZTS and UTHR?
Mankind Pharma's EBIT of ₹29,720 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Mankind Pharma. Mankind Pharma's current EBIT is ₹29,720 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,934.91, compared to a current price of ₹2,491.45 — trading 15.1% below its estimated fair value. The current EBIT is ₹29,720 Mil. Mankind Pharma's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current EBIT is ₹29,720 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mankind Pharma (BOM:543904) Overvalued in 2026?

Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued. The current stock price of ₹2,491.45 is trading 15.1% below its estimated GF Value™ of ₹2,934.91. GuruFocus considers Mankind Pharma to be Modestly Undervalued.

Key valuation signals for BOM:543904:

  • EBIT: ₹29,720 Mil
  • GF Value™: ₹2,934.91 vs. price of ₹2,491.45 (15.1% below fair value)
  • GF Score™: 90/100 with 6 warning signs

No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mankind Pharma Business Description

Other Exchanges MANKIND:India
Address 262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
90GF Score

Get the complete analysis for BOM:543904

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,491.45
Price
₹2,934.91
GF Value